The rationale for omitting pertuzumab was based on prior from both NeoSphere4 and CALGB 406019 suggesting the limited incremental benefit of dual HER2 blockade on pCR rates in patients with ER+ and/or PR+/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.